Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies designed to make biologics and injectable drugs accessible by mouth rather than injection. The company's proprietary RaniPill capsule platform uses a self-inflating balloon and microneedles to deliver diverse drug substances—including antibodies, proteins, peptides, and oligonucleotides—directly through the intestinal wall, achieving bioavailability comparable to subcutaneous administration. Rani operates a pipeline of oral drug candidates for obesity, inflammatory conditions, and other indications, generates revenue through partnerships and licensing deals with biopharmaceutical companies seeking to reformulate their existing biologics for oral delivery, and manufactures its platform in-house to protect intellectual property while maintaining control over manufacturing innovation.